Extended Data Fig. 6: The prevalence of the apg homologs in the intestinal microbiota of T2DM patients.
From: Inactivation of the antidiabetic drug acarbose by human intestinal microbial-mediated degradation
a, The prevalence of the apg homologs in the intestinal microbiota of 393 enrolled T2DM patients included in the metagenomic analyses. LR: low drug responders; HR: high drug responders. b, The prevalence of the apg homologs in the intestinal microbiota of 22 randomly selected T2DM patients with high or low response to the drug (11 from each group). The intestinal microorganisms in fecal samples of the patients were tested in acarbose metabolism using an ex vivo system. The parameters used to assess the metagenomic abundance of apg homologs in T2DM patients are as follows: identity ≥ 80%, e-value ≤1e − 10 and percent coverage of query and target alignment ≥ 80%.
